Abstract
Objective: Through comparativing the change of the ER, PR and HER-2 expression in tumor tissue before and after neoadjuvant chemotherapy (NAC) in locally advanced breast cancer patient, to discuss whether there is influence for NACon ER, PR, HER-2 expression for breast cancer. Also, the relationship of ER, PR, HER-2 and chemosensitivity is also discussed. Methods: The expressions of ER, PR and HER2 in paraffin sections of breast cancer tissues from 51 patients before and after NAC were detected by immunohistochemical method. The assessment for the relationships between ER, PR, HER-2 and the efficiently of NAC is done. Results: For the 51 peoples, there is no statistical significance for change of ER, PR and HER-2 expression before and after NAC (P > 0.05). There is statistical significance for the differences of chemotherapeutic effectiverate between ER negative and ER positive, PR negative and PR positive, HER2 over-expressed group and HER2 non over-expressed group (P < 0.05). Pathological complete response (pCR) was related to molecular classification and the number of chemotherapy cycles. There is statistically significant or prognisis difference about hormone receptor, HER2 over-expressed and three-negative breast cancer (P < 0.05). Conclusion: NAC maybe could not change the expression of ER and PR, and HER2 for breast cancer patients. The patients with HER-2 over-expressed are not sensitive to chemotherapy, and the patients with ER or PR negative get more benefits from chemotherapy. The breast cancer patients who could obtain pCR could get better prognosis after NAC.
Highlights
We examined the expression of ER, PR and HER2 in tumor tissues before and after neoadjuvant chemotherapy in 51 patients with locally advanced breast cancer, and compared them to understand the effect of NAC on these factors and the efficacy of neoadjuvant chemotherapy
This study concluded that hormone receptor-negative patients have better chemotherapy results, which may be because ER-negative tumors have better replication capacity than ER-positive tumors, so ER-negative tumors are more sensitive to chemotherapy than ER-positive tumors, and this sensitivity maybe increases as tumor expansion increases
The overexpression of HER2 predicts that the tumor has a strong invasive ability, and the tumor has a high possibility of malignancy, it is prone to recurrence and has a poor prognosis [17]
Summary
Breast cancer is the second most common malignant tumor in women. The number of infected people can reach more than 160,000 per year and it is the second common malignant tumor for women, the deaths can reach more than 40,000, accounting for 9.6% in the world [2]. For patients with locally advanced breast cancer, it is generally the preferred treatment. In this experiment, we examined the expression of ER, PR and HER2 in tumor tissues before and after neoadjuvant chemotherapy in 51 patients with locally advanced breast cancer, and compared them to understand the effect of NAC on these factors and the efficacy of neoadjuvant chemotherapy. The survival of different types of breast cancer patients was evaluated
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call